Journal
CANCER GENE THERAPY
Volume 28, Issue 10-11, Pages 1088-1098Publisher
SPRINGERNATURE
DOI: 10.1038/s41417-020-00279-0
Keywords
-
Categories
Funding
- VOLACOL project (Regione Lazio)
- PROPRIOCOLLOX (Beyond Borders Project) Universita Tor Vergata
Ask authors/readers for more resources
Recent studies have demonstrated a strong correlation between metabolic disorders, tumor onset, and progression, leading to the exploration of new therapeutic strategies targeting metabolic targets. The OLR1 gene encodes the LOX-1 receptor protein, which has been shown to be involved in atherosclerosis and more recently in various tumors. Upregulation of LOX-1 in tumors has been linked to cancer initiation, progression, and metastasis, indicating it as a promising therapeutic target for enhancing current antineoplastic strategies.
Recently, a strong correlation between metabolic disorders, tumor onset, and progression has been demonstrated, directing new therapeutic strategies on metabolic targets. OLR1 gene encodes the LOX-1 receptor protein, responsible for the recognition, binding, and internalization of ox-LDL. In the past, several studied, aimed to clarify the role of LOX-1 receptor in atherosclerosis, shed light on its role in the stimulation of the expression of adhesion molecules, pro-inflammatory signaling pathways, and pro-angiogenic proteins, including NF-kB and VEGF, in vascular endothelial cells and macrophages. In recent years, LOX-1 upregulation in different tumors evidenced its involvement in cancer onset, progression and metastasis. In this review, we outline the role of LOX-1 in tumor spreading and metastasis, evidencing its function in VEGF induction, HIF-1alpha activation, and MMP-9/MMP-2 expression, pushing up the neoangiogenic and the epithelial-mesenchymal transition process in glioblastoma, osteosarcoma prostate, colon, breast, lung, and pancreatic tumors. Moreover, our studies contributed to evidence its role in interacting with WNT/APC/beta-catenin axis, highlighting new pathways in sporadic colon cancer onset. The application of volatilome analysis in high expressing LOX-1 tumor-bearing mice correlates with the tumor evolution, suggesting a closed link between LOX-1 upregulation and metabolic changes in individual volatile compounds and thus providing a viable method for a simple, non-invasive alternative monitoring of tumor progression. These findings underline the role of LOX-1 as regulator of tumor progression, migration, invasion, metastasis formation, and tumor-related neo-angiogenesis, proposing this receptor as a promising therapeutic target and thus enhancing current antineoplastic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available